Restalyst is currently actively researching applications for the clinical diagnostics market, specifically in the areas of Neurodegeneration, and Oncology leveraging on its High-sensitivity Protein Diagnostic platform, Soluble Analyte Amplification (SAM) and its expertise in protein biology. SAM allows high-sensitivity, multiplexed detection of proteins in a range of clinical matrices. It allows users to detect both generic and novel biomarkers at sensitivity levels many magnitudes higher than existing assay systems. Restalyst's technology can also aid in the discovery of novel biomarkers and targets for both clinical applications and drug development. Restalyst is currently the market leader for nasopharyngeal cancer diagnostics in South East Asia with its NPC REAAD™ ELISA.
| Website | https://restalyst.com |
| Revenue | $1 million |
| Employees | 4 (0 on RocketReach) |
| Industry | Medical Testing & Clinical Laboratories, Healthcare |
| Keywords | Oncology Diagnostics, Clinical Diagnostics, Biomarker Discovery, Disease Diagnostics, Early Disease Detection, Cancer Diagnostics, Neurological Diagnostics, Diagnostic Platform, Precision Diagnostics, Molecular Diagnostics, Diagnostic Technology, In-Vitro Diagnostics, Clinical Research, Drug Discovery, Medical Diagnostics |
| Competitors | Yelp, Tripadvisor, Toast, Grubhub, Zomato, OpenTable, Foursquare, Resy, American Express Global Dining Network, Kai Sui Ramen, DoorDash Driver App +38 more (view full list) |
| SIC | SIC Code 8071 Companies, SIC Code 807 Companies, SIC Code 80 Companies |
| NAICS | NAICS Code 62151 Companies, NAICS Code 6215 Companies, NAICS Code 62 Companies, NAICS Code 621 Companies |
Looking for a particular Restalyst employee's phone or email?
Restalyst Questions
The Restalyst annual revenue was $1 million in 2026.
The NAICS codes for Restalyst are [62151, 6215, 62, 621].
The SIC codes for Restalyst are [8071, 807, 80].
